Paul A Carpenter, MD, MBBS
Cancer and Blood Disorders Center, Leukemia and Lymphoma Program, Non-Malignant Transplant Program, Pediatric Blood and Marrow Transplant Program
On staff since June 1999
Children's Title: Attending Physician, Pediatric Blood and Marrow Transplant, Cancer and Blood Disorders Center
Academic Title: Professor, Department of Pediatrics, University of Washington School of Medicine
Research Center: Ben Towne Center for Childhood Cancer Research
"One of the most rewarding aspects of my work is the privilege of forging long-term relationships with families who are faced with what must be one of the most challenging experiences of their lives caring for a child with a life-threatening disorder that is potentially treatable by stem cell transplantation. When I see patients, I try to listen attentively and maintain open communication. I focus on empowering patients and their families with evidence-based knowledge and offering them treatment options that focus on quality of life."
-
Biography
Paul Carpenter, MD, is an attending physician at Seattle Children's Hospital, clinical director for long term follow-up clinical service at Fred Hutchinson Cancer Center and a professor at the University of Washington, with a focus on graft-versus-host disease (GVHD). He supervises junior attending staff on the pediatric hematopoietic cell transplant service at Fred Hutchinson. His local responsibilities include long-standing contributions to the Fred Hutchinson Standard Practice Committee and Standard Practice Manual.
He chairs the American Society of Transplantation and Cellular Therapy's Committee on Practice Guidelines. His clinical and research interests focus on GVHD, which is the major and potentially lethal complication of hematopoietic cell transplant. His research continues to explore new therapies for the treatment of acute and chronic GVHD, and he is an active member in the national efforts to advance the field of chronic GVHD treatment. He is also interested in therapies designed to ameliorate key morbidities associated with chronic immunosuppressive therapies, such as bisphosphonate therapy for glucocorticoid-induced bone disease and the use of statins to treat hyperlipidemia. He has designed and participated in studies to evaluate the safety and efficacy of tyrosine kinase inhibitors as post-transplant therapy for high-risk Philadelphia chromosomepositive leukemias and for the treatment of chronic graft versus host disease. He was the principal investigator of the inaugural Blood and Marrow Clinical Trials Network (BMT CTN) Phase II/III 0801 trial for chronic graft-versus-host-disease.
-
Related Pages
-
-
Patient Testimonials
-
I would like to recommend Dr. Carpenter and the whole Bone Marrow Transplant team for their expertise in what they’re doing to give my child a chance to live after a horrendous cancer journey. Kudos to you all!
-
-
Awards and Honors
Award Name Award Description Awarded By Award Date SEATTLE TOP DOCTOR - 2022 Seattle Magazine 2022 SEATTLE'S TOP DOCTOR - 2017 Seattle Magazine 2017 SEATTLE MAGAZINE TOP DOCTOR - 2016 Seattle Magazine 2016 SEATTLE MAGAZINE TOP DOCTOR - 2016 Seattle Magazine 2016 Newsweek Health: Top Cancer Doctors 2015 Newsweek 2015
Overview
- Board Certification(s)
-
Pediatrics
- Medical/Professional School
-
University of Sydney Faculty of Medicine, Sydney
- Residency
-
Royal Sydney Children's Hospital, Randwick
- Fellowship
-
Royal Sydney Children's Hospital, Randwick
University of Washington School of Medicine, Seattle, WA - Clinical Interests
-
Graft vs. host disease
Long-term follow-up after hematopoetic cell transplantation